대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Efficacy of Denosumab for Hemodialysis Patients with low Bone Mineral Density
저자	Seung Hyun Han, Hyunga Jo, Kum Hyun Han, Sang Youb Han
출판정보	2020; 2020(1):
키워드	Denosumab \| Hemodialysis \| Bone mineral density
초록	The incidence of fractures is much higher in patients with chronic kidney disease (CKD), especially hemodialysis (HD), than people without CKD. Denosumab, a RANKL inhibitor, is known to be an effective anti-osteoporotic agent for patients with osteoporosis by reducing osteoclast activity. However, the guidelines of denosumab use based on its concrete effect on HD have not been established. Thus, we determined the effectiveness of denosumab in HD patients. A bone densitometry, dual-energy x-ray absorptiometry (DXA), was performed in 91 hemodialysis patients. Thirty-seven patients were treated with denosumab. We conducted observational retrospective analysis of 23 HD patients who were treated with denosumab for more than 6 months. Serum bone turnover markers were measured at 6 months and bone mineral density (BMD) was evaluated using DXA 1 year after treatment. After denosumab treatment, BMD and serum bone turnover markers were restored. The BMD of femur neck and lumbar spine were improved 3.40 ± 7.3% and 4.96 ± 4.6%, respectively. The T-score of femur neck and lumbar spine were increased 0.153 ± 0.3 (P=0.052) and 0.323 ± 0.35 (P=0.001), respectively. The level of C-terminal telopeptide, a bone resorption marker, significantly decreased from 2.27 ± 0.22 to 1.36 ± 0.18 ng/mL (p=0.001) after 6 months of denosumab treatment. The level of bone specific alkaline phosphatase, a bone formation marker, also decreased from 63.86 ± 6.37 to 30.44 ± 2.38 IU/L (p<0.001). However, there is no significant change in the level of osteocalcin. Three patients showed numbness related to hypocalcemia. Two patients among them suffered from sustained hypocalcemia for 2 months after the treatment. There was no occurrence of hypocalcemia after active prevention with calcium and calcitriol. In conclusion, denosumab could improve bone density in HD patients. These result suggests the potential efficacy of denosumab in HD patients with low BMD.
원문(PDF)	PDF 원문보기

목록

위로가기